Galectin Therapeutics Inc. (GALT)

[thefamilyman]

I am glad that they are targeting cirrhosis because that is the final stage before death. When the alternative is death, it is easier to get patients enrolled in your trial. And I would think that under those circumstances there would be more pressure to move an efficacious drug through the FDA process.

Remember the multi-billion dollar increase in ICPT's market cap was because it's NASH drug was stopped halfway through the Phase 2 because of efficacy. (And ICPT's drug is apparently more of a preventative than a treatment.) Since GALT's drug is apparently a treatment that will reverse fibrosis, hopefully GALT will see the exact same thing happen with our Phase 2 and with our market cap.

I hope the final results from cohort 3 will share a little more data and give us a little more of a peek at trial design for phase 2 and firmer dates. With that said, I think it's pretty impressive that GALT is aiming as high as they are in targeting cirrhotic patients for the upcoming trial. Measuring HPV pressure as an indicator of efficacy is really interesting too. If that shows significant reduction, I would think we would really have something. The complications from increased HPV pressure are some of the greatest survival risks to cirrhotic patients. - Darwinian